SCHEMBL4873796

SCHEMBL4873796

O=C(O)CCCCCCCCCCCNC(=O)C(O)CCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 1/20 0.53
FFAR1 O14842 1/20 0.46
EPHX2 P34913 2/20 0.46
HRH3 Q9Y5N1 1/20 0.45
MAPK1 P28482 1/20 0.45
PLAAT3 P53816 1/20 0.44
PLAAT5 Q96KN8 1/20 0.44
PLAAT2 Q9NWW9 1/20 0.44
PLAAT4 Q9UL19 1/20 0.44
SLC6A5 Q9Y345 2/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HDAC1 Q13547 3/20 0.43
HDAC8 Q9BY41 3/20 0.43
HDAC3 O15379 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4874708 0.88 EPHX2 (0.47) PTGFRFFAR1EPHX2HRH3MAPK1
SCHEMBL4870358 0.87 HRH3 (0.43) PTGFRHRH3PLAAT3PLAAT5PLAAT2
SCHEMBL4881753 0.80 NAAA (0.52) PTGFREPHX2MAPK1CYP1A2CYP2C9
SCHEMBL25172817 0.77 MAPT (0.62) PTGFRFFAR1MAPK1HDAC1HDAC8
SCHEMBL23176837 0.77 MAPT (0.62) PTGFRFFAR1MAPK1HDAC1HDAC8
SCHEMBL27742525 0.77 LMNA (0.59) MAPK1CYP2C9CYP2C19HDAC1HDAC8
SCHEMBL4037431 0.76 HDAC1 (0.59) PTGFRFFAR1MAPK1PLAAT3PLAAT5
SCHEMBL4882435 0.74 EPHX2 (0.61) FFAR1EPHX2PLAAT3PLAAT5PLAAT2
SCHEMBL1454387 0.74 FFAR1 (0.60) PTGFRFFAR1MAPK1PLAAT3PLAAT5
SCHEMBL4780175 0.73 LMNA (0.57) MAPK1CYP2C9CYP2C19HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
WO-2008073623-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 PTGFR 340/4885FFAR1 350/4885EPHX2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.